Equities

Milestone Medical Inc

MMD:WSE

Milestone Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (PLN)1.58
  • Today's Change0.00 / 0.00%
  • Shares traded5.00
  • 1 Year change-16.84%
  • Beta--
Data delayed at least 15 minutes, as of Dec 18 2023.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Milestone Medical, Inc. develops epidural and intra-articular drug delivery systems based on patented, painless, computer-controlled injection and drug delivery technology. Its CompuFlo Epidural System provides anesthesiologists and other health care providers with the ability to determine and document the pressure at the needle tip in real-time. Its CompuFlo Epidural's DPS Dynamic Pressure Sensing Technology (DPS) allows the CompuFlo Epidural to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify the epidural space. The DPS instrument is a patented computer-controlled injection system geared to the needs of the medical market. The Company’s is also focused on marketing the Epidural medical and trainer instruments in the United States. The Company’s products include medical instruments, handpieces/disposables, and other related products. It sells its products primarily through medical facilities and a global distribution network.

  • Revenue in PLN (TTM)29.12k
  • Net income in PLN-13.86m
  • Incorporated2011
  • Employees4.00
  • Location
    Milestone Medical Inc425 Eagle Rock Ave, Suite 403ROSELAND 07068United StatesUSA
  • Phone+1 (973) 535-2717
  • Fax+1 (973) 535-2829
  • Websitehttps://medicalmilestone.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Clinical Laserthermia Systems AB4.05m-26.53m21.14m7.00--1.20--5.22-15.31-15.312.006.000.217312.584.86---144.45-123.49-259.50-312.95-392.44-1,084.16-664.90-1,625.032.06-30.970.0094--31.9935.55-12.92--18.61--
Nestmedic SA1.33m-6.07m21.45m8.00--4.34--16.18-0.2674-0.26740.05770.17960.10170.10282.44147,303.30-46.61-56.34-79.38-112.8871.9249.09-458.08-497.001.27-21.030.1887---8.5070.26-30.83---60.10--
iZafe Group AB1.87m-12.26m21.79m7.00--2.94--11.64-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
Surgical Innovations Group Plc60.30m-2.55m23.41m101.00--0.444918.810.3882-0.0005-0.00050.01290.01120.80322.855.89118,950.50-3.40-8.19-4.18-9.9428.7032.51-4.24-13.311.23-4.450.1368--5.941.84-292.80--7.20--
Kontigo Care AB11.02m289.96k25.18m10.0064.001.8814.812.280.03280.03281.171.120.6807--7.69--1.79-0.42142.55-0.619568.8466.312.63-0.5205--4.000.093--1.8016.95-92.68--44.94--
Glycorex Transplantation AB (publ)11.60m-11.05m26.36m15.00--1.82--2.27-0.40-0.400.41970.54850.39780.72834.601,347,652.00-37.91-11.30-47.48-13.1784.7991.60-95.30-33.241.20-118.900.2046---17.04-2.15-254.06---0.5593--
Myhealthchecked PLC75.01m948.58k29.69m15.0030.660.691917.870.39580.00370.00370.28850.16441.265.817.95996,400.001.59-20.092.21-28.2327.7922.621.26-13.423.53--0.0047--36.26190.36-24.30---12.80--
AtomTrace as-17.31bn-17.31bn31.04m-----------------------------135.43---349.63---252.08---574.34---------97.23-61.898.76------
BBS-Bioactive Bone Substitutes Oyj0.00-14.88m31.38m----1.37-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
Milestone Medical Inc29.12k-13.86m34.62m4.00------1,189.04-0.6302-0.63020.0013-5.070.01090.59180.1213---517.54-340.87-----3,337.03-166.46-47,612.84-5,029.090.0067-34.89-----65.3492.41-16.23------
Redsense Medical AB (publ)7.43m-2.83m35.41m5.00--4.76--4.77-0.5389-0.53891.411.420.72614.515.023,970,800.00-27.67-18.66-31.75-20.9950.1169.02-38.11-46.282.21--0.00--74.1128.9448.47---23.62--
Luxbright AB356.52k-9.49m35.71m10.00--2.83--100.16-0.2752-0.27520.01030.36530.0265--1.9995,290.00-70.61-61.39-81.90-70.36-947.28-559.15-2,662.94-2,459.34---1,722.290.0061--73.46---20.07------
Observe Medical ASA10.49m-22.65m35.78m12.00--0.8247--3.41-1.05-1.050.48490.60630.11912.497.122,328,500.00-25.72-32.60-35.90-49.8033.2432.83-216.03-256.250.334-6.010.3204--43.14204.81-18.82--32.69--
Rua Life Sciences PLC9.38m-9.39m37.38m40.00--0.713--3.98-0.0843-0.08430.08430.16830.32933.264.8046,725.00-32.95-25.97-36.33-28.2681.97---100.05-110.532.40-61.710.1065--34.0940.083.10--94.82--
ScandiDos AB24.35m-1.81m38.39m34.00--2.37--1.58-0.1063-0.10631.430.75880.95730.47877.39---7.14-13.82-13.39-23.9582.5482.49-7.45-17.090.4511-2.630.00--6.704.01-24.27--4.18--
Nanexa AB10.82m-26.42m47.82m19.00--1.37--4.42-0.8143-0.81430.32520.68540.2069-33.452.261,521,474.00-50.54-40.77-66.82-48.77124.7077.27-244.28-532.262.14--0.0193--925.42147.00-30.44--39.10--
Data as of Dec 18 2023. Currency figures normalised to Milestone Medical Inc's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.